Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness?
Eur J Health Econ
.
2015 May;16(4):341-5.
doi: 10.1007/s10198-014-0653-x.
Authors
Katelijne van de Vooren
1
,
Alessandro Curto
,
Livio Garattini
Affiliation
1
CESAV, Center for Health Economics, IRCCS Institute for Pharmacological Research 'Mario Negri', Via Camozzi 3, 24020, Ranica, Italy.
PMID:
25407841
DOI:
10.1007/s10198-014-0653-x
No abstract available
Publication types
Editorial
MeSH terms
Antiviral Agents / economics*
Antiviral Agents / therapeutic use
Cost-Benefit Analysis
Drug Costs*
Europe
Health Policy / economics
Hepatitis C / drug therapy
Hepatitis C / economics*
Humans
Substances
Antiviral Agents